A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in the companies’ phase 3 clinical trial, Pfizer and BioNTech announced yesterday. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose, the companies said. They plan to submit the updated data to the Food and Drug Administration, which in May expanded the vaccine’s emergency use authorization to include 12-15 year olds. 

Related News Articles

News
President Biden today called the new Omicron variant of the COVID-19 virus “a cause for concern, not a cause for panic,” urging all eligible Americans to get…
News
The U.S. District Court for the Eastern District of Missouri today granted a preliminary injunction preventing the Centers for Medicare & Medicaid Services…
Headline
The Department of Health and Human Services today began distributing $7.5 billion of the $8.5 billion in American Rescue Plan Act payments designated for…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
The Health Resources and Services Administration in September gave health care providers who received more than $10,000 in Provider Relief Funds between April…
Headline
The AHA, American Medical Association and American Nurses Association today released a television and digital ad in English and Spanish thanking…